|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shahab D, Gabriel E, Attwood K, Ma WW,
Francescutti V, Nurkin S and Boland PM: Adjuvant chemotherapy is
associated with improved overall survival in locally advanced
rectal cancer after achievement of a pathologic complete response
to chemoradiation. Clin Colorectal Cancer. 16:300–307. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fujita K, Taneishi K, Inamoto T, Ishizuya
Y, Takada S, Tsujihata M, Tanigawa G, Minato N, Nakazawa S, Takada
T, et al: Adjuvant chemotherapy improves survival of patients with
high-risk upper urinary tract urothelial carcinoma: A propensity
score-matched analysis. BMC Urol. 17:1102017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lu JM, Yao Q and Chen C: Ginseng
compounds: An update on their molecular mechanisms and medical
applications. Curr Vasc Pharmacol. 7:293–302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hou J, Xue J, Lee M, Liu L, Zhang D, Sun
M, Zheng Y and Sung C: Ginsenoside Rh2 improves learning and memory
in mice. J Med Food. 16:772–776. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qian Y, Huang R, Li S, Xie R, Qian B,
Zhang Z, Li L, Wang B, Tian C, Yang J, et al: Ginsenoside Rh2
reverses cyclophosphamide-induced immune deficiency by regulating
fatty acid metabolism. J Leukoc Biol. 106:1089–1100. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Choi WY, Lim HW and Lim CJ:
Anti-inflammatory, antioxidative and matrix metalloproteinase
inhibitory properties of 20(R)-ginsenoside Rh2 in cultured
macrophages and keratinocytes. J Pharm Pharmacol. 65:310–316. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang XP, Li KR, Yu Q, Yao MD, Ge HM, Li
XM, Jiang Q, Yao J and Cao C: Ginsenoside Rh2 inhibits vascular
endothelial growth factor-induced corneal neovascularization. FASEB
J. 32:3782–3791. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou J, Gao Y, Yi X and Ding Y:
Ginsenoside Rh2 suppresses neovascularization in xenograft
psoriasis model. Cell Physiol Biochem. 36:980–987. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Choi K, Kim M, Ryu J and Choi C:
Ginsenosides compound K and Rh(2) inhibit tumor necrosis
factor-alpha-induced activation of the NF-kappaB and JNK pathways
in human astroglial cells. Neurosci Lett. 421:37–41. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bae EA, Kim EJ, Park JS, Kim HS, Ryu JH
and Kim DH: Ginsenosides Rg3 and Rh2 inhibit the activation of AP-1
and protein kinase A pathway in
lipopolysaccharide/interferon-gamma-stimulated BV-2 microglial
cells. Planta Med. 72:627–633. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y, Wang H, Liu Y, Li C, Qi P and Bao
J: Antihyperglycemic effect of ginsenoside Rh2 by inducing islet
β-cell regeneration in mice. Horm Metab Res. 44:33–40. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang YQ, Huang HX, Han ZD, Li W, Mai ZP
and Yuan RQ: Ginsenoside Rh2 Inhibits Angiogenesis in Prostate
Cancer by Targeting CNNM1. J Nanosci Nanotechnol. 19:1942–1950.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tong-Lin Wu T, Tong YC, Chen IH, Niu HS,
Li Y and Cheng JT: Induction of apoptosis in prostate cancer by
ginsenoside Rh2. Oncotarget. 9:11109–11118. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi X, Yang J and Wei G: Ginsenoside
20(S)-Rh2 exerts anti-cancer activity through the Akt/GSK3β
signaling pathway in human cervical cancer cells. Mol Med Rep.
17:4811–4816. 2018.PubMed/NCBI
|
|
16
|
Wang YS, Lin Y, Li H, Li Y, Song Z and Jin
YH: The identification of molecular target of (20S) ginsenoside Rh2
for its anti-cancer activity. Sci Rep. 7:124082017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang J, Yuan D, Xing T, Su H, Zhang S, Wen
J, Bai Q and Dang D: Ginsenoside Rh2 inhibiting HCT116 colon cancer
cell proliferation through blocking PDZ-binding kinase/T-LAK
cell-originated protein kinase. J Ginseng Res. 40:400–408. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Han S, Jeong AJ, Yang H, Bin Kang K, Lee
H, Yi EH, Kim BH, Cho CH, Chung JW, Sung SH and Ye SK: Ginsenoside
20(S)-Rh2 exerts anti-cancer activity through targeting
IL-6-induced JAK2/STAT3 pathway in human colorectal cancer cells. J
Ethnopharmacol. 194:83–90. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim MJ, Yun H, Kim DH, Kang I, Choe W, Kim
SS and Ha J: AMP-activated protein kinase determines apoptotic
sensitivity of cancer cells to ginsenoside-Rh2. J Ginseng Res.
38:16–21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tang XP, Tang GD, Fang CY, Liang ZH and
Zhang LY: Effects of ginsenoside Rh2 on growth and migration of
pancreatic cancer cells. World J Gastroenterol. 19:1582–1592. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li KF, Kang CM, Yin XF, Li HX, Chen ZY, Li
Y, Zhang Q and Qiu YR: Ginsenoside Rh2 inhibits human A172 glioma
cell proliferation and induces cell cycle arrest status via
modulating Akt signaling pathway. Mol Med Rep. 17:3062–3068.
2018.PubMed/NCBI
|
|
22
|
Ge G, Yan Y and Cai H: Ginsenoside Rh2
inhibited proliferation by inducing ROS mediated ER stress
dependent apoptosis in lung cancer cells. Biol Pharma Bull.
40:2117–2124. 2017. View Article : Google Scholar
|
|
23
|
Li H, Huang N, Zhu W, Wu J, Yang X, Teng
W, Tian J, Fang Z, Luo Y, Chen M and Li Y: Modulation the crosstalk
between tumor-associated macrophages and non-small cell lung cancer
to inhibit tumor migration and invasion by ginsenoside Rh2. BMC
Cancer. 18:5792018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
An IS, An S, Kwon KJ, Kim YJ and Bae S:
Ginsenoside Rh2 mediates changes in the microRNA expression profile
of human non-small cell lung cancer A549 cells. Oncol Rep.
29:523–528. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen Y, Zhang Y, Song W, Zhang Y, Dong X
and Tan M: Ginsenoside Rh2 inhibits migration of lung cancer cells
under hypoxia via mir-491. Anticancer Agents Med Chem.
19:1633–1641. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cheng CC, Yang SM, Huang CY, Chen JC,
Chang WM and Hsu SL: Molecular mechanisms of ginsenoside
Rh2-mediated G1 growth arrest and apoptosis in human lung
adenocarcinoma A549 cells. Cancer Chemother Pharmacol. 55:531–540.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen W, Chu S, Li H and Qiu Y:
MicroRNA-146a-5p enhances ginsenoside Rh2-induced
anti-proliferation and the apoptosis of the human liver cancer cell
line HepG2. Oncol Lett. 16:5367–5374. 2018.PubMed/NCBI
|
|
28
|
Chen W and Qiu Y: Ginsenoside Rh2 Targets
EGFR by up-regulation of miR-491 to enhance anti-tumor activity in
hepatitis B virus-related hepatocellular carcinoma. Cell Biochem
Biophys. 72:325–331. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qian J, Li J, Jia JG, Jin X, Yu DJ, Guo
CX, Xie B and Qian LY: Ginsenoside-Rh2 inhibits proliferation and
induces apoptosis of human gastric cancer SGC-7901 side population
cells. Asian Pac J Cancer Prev. 17:1817–1821. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li B, Zhao J, Wang CZ, Searle J, He TC,
Yuan CS and Du W: Ginsenoside Rh2 induces apoptosis and
paraptosis-like cell death in colorectal cancer cells through
activation of p53. Cancer Lett. 301:185–192. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu C, Liu F, Qian W, Zhang T and Li F:
Combined effect of sodium selenite and Ginsenoside Rh2 on hct116
human colorectal carcinoma cells. Arch Iran Med. 19:23–29.
2016.PubMed/NCBI
|
|
32
|
Oh M, Choi YH, Choi S, Chung H, Kim K, Kim
SI, Kim DK and Kim ND: Anti-proliferating effects of ginsenoside
Rh2 on MCF-7 human breast cancer cells. Int J Oncol. 14:869–875.
1999.PubMed/NCBI
|
|
33
|
Lee H, Lee S, Jeong D and Kim SJ:
Ginsenoside Rh2 epigenetically regulates cell-mediated immune
pathway to inhibit proliferation of MCF-7 breast cancer cells. J
Ginseng Res. 42:455–462. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Choi S, Kim TW and Singh SV: Ginsenoside
Rh2-mediated G1 phase cell cycle arrest in human breast cancer
cells is caused by p15 Ink4B and p27 Kip1-dependent inhibition of
cyclin-dependent kinases. Pharm Res. 26:2280–2288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu J, Shimizu K, Yu H, Zhang C, Jin F and
Kondo R: Stereospecificity of hydroxyl group at C-20 in
antiproliferative action of ginsenoside Rh2 on prostate cancer
cells. Fitoterapia. 81:902–905. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Q, Hong B, Wu S and Niu T:
Inhibition of prostatic cancer growth by ginsenoside Rh2. Tumour
Biol. 36:2377–2381. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gao Q and Zheng J: Ginsenoside Rh2
inhibits prostate cancer cell growth through suppression of
microRNA-4295 that activates CDKN1A. Cell Prolif. 51:e124382018.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xia T, Wang YN, Zhou CX, Wu LM, Liu Y,
Zeng QH, Zhang XL, Yao JH, Wang M and Fang JP: Ginsenoside Rh2 and
Rg3 inhibit cell proliferation and induce apoptosis by increasing
mitochondrial reactive oxygen species in human leukemia Jurkat
cells. Mol Med Rep. 15:3591–3598. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xia T, Wang J, Wang Y, Wang Y, Cai J, Wang
M, Chen Q, Song J, Yu Z, Huang W and Fang J: Inhibition of
autophagy potentiates anticancer property of 20(S)-ginsenoside Rh2
by promoting mitochondria-dependent apoptosis in human acute
lymphoblastic leukaemia cells. Oncotarget. 7:27336–27349. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Huang J, Peng K, Wang L, Wen B, Zhou L,
Luo T, Su M, Li J and Luo Z: Ginsenoside Rh2 inhibits proliferation
and induces apoptosis in human leukemia cells via TNF-alpha
signaling pathway. Acta Biochim Biophys Sin (Shanghai). 48:750–755.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen Y, Liu ZH, Xia J, Li XP, Li KQ, Xiong
W, Li J and Chen DL: 20(S)-ginsenoside Rh2 inhibits the
proliferation and induces the apoptosis of KG-1a cells through the
Wnt/β-catenin signaling pathway. Oncol Rep. 36:137–146. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nakata H, Kikuchi Y, Tode T, Hirata J,
Kita T, Ishii K, Kudoh K, Nagata I and Shinomiya N: Inhibitory
effects of ginsenoside Rh2 on tumor growth in nude mice bearing
human ovarian cancer cells. Jpn J Cancer Res. 89:733–740. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tode T, Kikuchi Y, Kita T, Hirata J,
Imaizumi E and Nagata I: Inhibitory effects by oral administration
of ginsenoside Rh2 on the growth of human ovarian cancer cells in
nude mice. J Cancer Res Clin Oncol. 120:24–26. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li N, Lin Z, Chen W, Zheng Y, Ming Y,
Zheng Z, Huang W, Chen L, Xiao J and Lin H: Corilagin from longan
seed: Identification, quantification, and synergistic cytotoxicity
on SKOv3ip and hey cells with ginsenoside Rh2 and 5-fluorouracil.
Food Chem Toxicol. 119:133–140. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim JH and Choi JS: Effect of ginsenoside
Rh-2 via activation of caspase-3 and Bcl-2-insensitive pathway in
ovarian cancer cells. Physiol Res. 65:1031–1037. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang C, Yu H and Hou J: Effects of 20
(S)-ginsenoside Rh2 and 20 (R)-ginsenoside Rh2 on proliferation and
apoptosis of human lung adenocarcinoma A549 cells. Zhongguo Zhong
Yao Za Zhi. 36:1670–1674. 2011.(In Chinese). PubMed/NCBI
|
|
47
|
Dong H, Bai LP, Wong VK, Zhou H, Wang JR,
Liu Y, Jiang ZH and Liu L: The in vitro structure-related
anti-cancer activity of ginsenosides and their derivatives.
Molecules. 16:10619–10630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Harashima H, Dissmeyer N and Schnittger A:
Cell cycle control across the eukaryotic kingdom. Trends Cell Biol.
23:345–356. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Roskoski R Jr: Cyclin-dependent protein
serine/threonine kinase inhibitors as anticancer drugs. Pharmacol
Res. 139:471–488. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Abbas T and Dutta A: p21 in cancer:
Intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liu X, Sun Y, Yue L, Li S, Qi X, Zhao H,
Yang Y, Zhang C and Yu H: JNK pathway and relative transcriptional
factor were involved in ginsenoside Rh2-mediated G1 growth arrest
and apoptosis in human lung adenocarcinoma A549 cells. Genet Mol
Res. 15:2016. View Article : Google Scholar
|
|
52
|
Chung KS, Cho SH, Shin JS, Kim DH, Choi
JH, Choi SY, Rhee YK, Hong HD and Lee KT: Ginsenoside Rh2 induces
cell cycle arrest and differentiation in human leukemia cells by
upregulating TGF-β expression. Carcinogenesis. 34:331–340. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fuchs Y and Steller H: Programmed cell
death in animal development and disease. Cell. 147:742–758. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Plati J, Bucur O and Khosravi-Far R:
Dysregulation of apoptotic signaling in cancer: Molecular
mechanisms and therapeutic opportunities. J Cell Biochem.
104:1124–1149. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Guo XX, Li Y, Sun C, Jiang D, Lin YJ, Jin
FX, Lee SK and Jin YH: p53-dependent Fas expression is critical for
Ginsenoside Rh2 triggered caspase-8 activation in HeLa cells.
Protein Cell. 5:224–234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wang X and Wang Y: Ginsenoside Rh2
mitigates pediatric leukemia through suppression of Bcl-2 in
leukemia cells. Cell Physiol Biochem. 37:641–650. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Li Q, Li Y, Wang X, Fang X, He K, Guo X,
Zhan Z, Sun C and Jin YH: Co-treatment with ginsenoside Rh2 and
betulinic acid synergistically induces apoptosis in human cancer
cells in association with enhanced capsase-8 activation, bax
translocation, and cytochrome c release. Mol Carcinog. 50:760–769.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Manning BD and Cantley LC: AKT/PKB
signaling: Navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Liu ZH, Li J, Xia J, Jiang R, Zuo GW, Li
XP, Chen Y, Xiong W and Chen DL: Ginsenoside 20(s)-Rh2 as potent
natural histone deacetylase inhibitors suppressing the growth of
human leukemia cells. Chem Biol Interact. 242:227–234. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhang H, Yi J, Kim E, Choo Y, Hai H, Kim
K, Kim EK, Ryoo Z and Kim M: 20(S)-Ginsenoside Rh2 suppresses oral
cancer cell growth by inhibiting the Src-Raf-ERK signaling pathway.
Anticancer Res. 41:227–235. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wu N, Wu GC, Hu R, Li M and Feng H:
Ginsenoside Rh2 inhibits glioma cell proliferation by targeting
microRNA-128. Acta Pharmacol Sin. 32:345–353. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ishay-Ronen D, Diepenbruck M, Kalathur
RKR, Sugiyama N, Tiede S, Ivanek R, Bantug G, Morini MF, Wang J,
Hess C and Christofori G: Gain fat-lose metastasis: Converting
invasive breast cancer cells into adipocytes inhibits cancer
metastasis. Cancer Cell. 35:17–32.e6. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kim JH, Kim M, Yun SM, Lee S, No JH, Suh
DH, Kim K and Kim YB: Ginsenoside Rh2 induces apoptosis and
inhibits epithelial-mesenchymal transition in HEC1A and Ishikawa
endometrial cancer cells. Biomed Pharmacother. 96:871–876. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhang BP, Li B, Cheng JY, Cao R, Gao ST,
Huang CJ, Li RP, Ning J, Liu B and Li ZG: Anti-cancer Effect of
20(S)-Ginsenoside-Rh2 on oral squamous cell carcinoma cells via the
decrease in ROS and downregulation of MMP-2 and VEGF. Biomed
Environ Sci. 33:713–717. 2020.PubMed/NCBI
|
|
68
|
Riabov V, Gudima A, Wang N, Mickley A,
Orekhov A and Kzhyshkowska J: Role of tumor associated macrophages
in tumor angiogenesis and lymphangiogenesis. Front Physiol.
5:752014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Goumans MJ, Liu Z and ten Dijke P:
TGF-beta signaling in vascular biology and dysfunction. Cell Res.
19:116–127. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Fidler IJ and Ellis LM: The implications
of angiogenesis for the biology and therapy of cancer metastasis.
Cell. 79:185–188. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Wang Q, Wu MQ, Zhao LH, Yang HK and Lv XH:
Effect of ginsenoside Rh2 on transplanted-tumor and expression of
JAM in mice. Zhongguo Zhong Yao Za Zhi. 33:2116–2119. 2008.(In
Chinese). PubMed/NCBI
|
|
72
|
Mizushima N, Levine B, Cuervo AM and
Klionsky DJ: Autophagy fights disease through cellular
self-digestion. Nature. 451:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ryan KM: p53 and autophagy in cancer:
Guardian of the genome meets guardian of the proteome. Eur J
Cancer. 47:44–50. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zhuang J, Yin J, Xu C, Mu Y and Lv S:
20(S)-Ginsenoside Rh2 Induce the Apoptosis and Autophagy in U937
and K562 Cells. Nutrients. 10:3282018. View Article : Google Scholar
|
|
75
|
Klionsky DJ, Abdelmohsen K, Abe A, Abedin
MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD,
Adeli K, et al: Guidelines for the use and interpretation of assays
for monitoring autophagy (3rd edition). Autophagy. 12:1–222. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Liu S, Chen M, Li P, Wu Y, Chang C, Qiu Y,
Cao L, Liu Z and Jia C: Ginsenoside rh2 inhibits cancer stem-like
cells in skin squamous cell carcinoma. Cell Physiol Biochem.
36:499–508. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Li M, Zhang D, Cheng J, Liang J and Yu F:
Ginsenoside Rh2 inhibits proliferation but promotes apoptosis and
autophagy by down-regulating microRNA-638 in human retinoblastoma
cells. Exp Mol Pathol. 108:17–23. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Ma J, Gao G, Lu H, Fang D, Li L, Wei G,
Chen A, Yang Y, Zhang H and Huo J: Reversal effect of ginsenoside
Rh2 on oxaliplatin-resistant colon cancer cells and its mechanism.
Exp Ther Med. 18:630–636. 2019.PubMed/NCBI
|
|
79
|
Zhou B, Xiao X, Xu L, Zhu L, Tan L, Tang
H, Zhang Y, Xie Q and Yao S: A dynamic study on reversal of
multidrug resistance by ginsenoside Rh(2) in adriamycin-resistant
human breast cancer MCF-7 cells. Talanta. 88:345–351. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Liu GW, Liu YH, Jiang GS and Ren WD: The
reversal effect of Ginsenoside Rh2 on drug resistance in human
colorectal carcinoma cells and its mechanism. Hum Cell. 31:189–198.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Lv DL, Chen L, Ding W, Zhang W, Wang HL,
Wang S and Liu WB: Ginsenoside G-Rh2 synergizes with SMI-4a in
anti-melanoma activity through autophagic cell death. Chin Med.
13:112018. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wang M, Yan SJ, Zhang HT, Li N, Liu T,
Zhang YL, Li XX, Ma Q, Qiu XC, Fan QY and Ma BA: Ginsenoside Rh2
enhances the antitumor immunological response of a melanoma mice
model. Oncol Lett. 13:681–685. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Xia T, Zhang B, Li Y, Fang B, Zhu XX, Xu
BC, Zhang J, Wang M and Fang JP: New insight into 20(S)-ginsenoside
Rh2 against T-cell acute lymphoblastic leukemia associated with the
gut microbiota and the immune system. Eur J Med Chem.
203:1125392020. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Li Q, Li B, Dong C, Wang Y and Li Q:
20(S)-Ginsenoside Rh2 suppresses proliferation and migration of
hepatocellular carcinoma cells by targeting EZH2 to regulate
CDKN2A-2B gene cluster transcription. Eur J Pharmacol. 815:173–180.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Shi Q, Shi X, Zuo G, Xiong W, Li H, Guo P,
Wang F, Chen Y, Li J and Chen DL: Anticancer effect of
20(S)-ginsenoside Rh2 on HepG2 liver carcinoma cells: Activating
GSK-3β and degrading β-catenin. Oncol Rep. 36:2059–2070. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Qian T, Cai Z, Wong RN and Jiang ZH:
Liquid chromatography/mass spectrometric analysis of rat samples
for in vivo metabolism and pharmacokinetic studies of ginsenoside
Rh2. Rapid Commun Mass Spectrom. 19:3549–3554. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Qi Z, Chen L, Li Z, Shao Z, Qi Y, Gao K,
Liu S, Sun Y, Li P and Liu J: Immunomodulatory effects of
(24R)-Pseudo-Ginsenoside HQ and (24S)-Pseudo-Ginsenoside HQ on
cyclophosphamide-induced immunosuppression and their anti-tumor
effects study. Int J Mol Sci. 20:8362019. View Article : Google Scholar
|
|
88
|
Gu Y, Wang GJ, Sun JG, Jia YW, Wang W, Xu
MJ, Lv T, Zheng YT and Sai Y: Pharmacokinetic characterization of
ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and
dogs. Food Chem Toxicol. 47:2257–2268. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Li S, Gao Y, Ma W, Guo W, Zhou G, Cheng T
and Liu Y: EGFR signaling-dependent inhibition of glioblastoma
growth by ginsenoside Rh2. Tumour Biol. 35:5593–5598. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Xia T, Wang JC, Xu W, Xu LH, Lao CH, Ye QX
and Fang JP: 20S-Ginsenoside Rh2 induces apoptosis in human
Leukaemia Reh cells through mitochondrial signaling pathways. Biol
Pharm Bull. 37:248–254. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Kim YS and Jin SH: Ginsenoside Rh2 induces
apoptosis via activation of caspase-1 and −3 and up-regulation of
Bax in human neuroblastoma. Arch Pharm Res. 27:834–839. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Shi Q, Li J, Feng Z, Zhao L, Luo L, You Z,
Li D, Xia J, Zuo G and Chen D: Effect of ginsenoside Rh2 on the
migratory ability of HepG2 liver carcinoma cells: Recruiting
histone deacetylase and inhibiting activator protein 1
transcription factors. Mol Med Rep. 10:1779–1785. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Guan N, Huo X, Zhang Z, Zhang S, Luo J and
Guo W: Ginsenoside Rh2 inhibits metastasis of glioblastoma
multiforme through Akt-regulated MMP13. Tumour Biol. 36:6789–6795.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Xia T, Zhang J, Zhou C, Li Y, Duan W,
Zhang B, Wang M and Fang J: 20(S)-Ginsenoside Rh2 displays efficacy
against T-cell acute lymphoblastic leukemia through the
PI3K/Akt/mTOR signal pathway. J Ginseng Res. 44:725–737. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Li S, Guo W, Gao Y and Liu Y: Ginsenoside
Rh2 inhibits growth of glioblastoma multiforme through mTor. Tumour
Biol. 36:2607–2612. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Li C, Gao H, Feng X, Bi C, Zhang J and Yin
J: Ginsenoside Rh2 impedes proliferation and migration and induces
apoptosis by regulating NF-κB, MAPK, and PI3K/Akt/mTOR signaling
pathways in osteosarcoma cells. J Biochem Mol Toxicol.
34:e225972020. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Yang D, Li X and Zhang X: Ginsenoside Rh2
induces DNA damage and autophagy in vestibular schwannoma is
dependent of LAMP2 transcriptional suppression. Biochem Biophys Res
Commun. 522:300–307. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Chen Y, Zhang Y, Song W, Zhang Y, Dong X
and Tan M: Ginsenoside Rh2 improves the cisplatin anti-tumor effect
in lung adenocarcinoma A549 cells via superoxide and PD-L1.
Anticancer Agents Med Chem. 20:495–503. 2020. View Article : Google Scholar : PubMed/NCBI
|
